Search results for "steatohepatitis"

showing 10 items of 134 documents

Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver

2015

Podoplanin/gp38+ stromal cells present in lymphoid organs play a central role in the formation and reorganization of the extracellular matrix and in the functional regulation of immune responses. Gp38+ cells are present during embryogenesis and in human livers of primary biliary cirrhosis. Since little is known about their function, we studied gp38+ cells during chronic liver inflammation in models of biliary and parenchymal liver fibrosis and steatohepatitis. Gp38+ cells were analyzed using flow cytometry and confocal microscopy, and the expression of their steady state and inflammation-associated genes was evaluated from healthy and inflamed livers. Gp38+ cells significantly expanded in …

Male0301 basic medicinePathologymedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BStromal cellPhysiologyLiver and Biliary Tract Physiology/PathophysiologyPopulationCell SeparationBiologyLiver Cirrhosis Experimental03 medical and health sciencesPrimary biliary cirrhosisAntigens CDNon-alcoholic Fatty Liver DiseasePhysiology (medical)medicineAnimalsAC133 AntigenProgenitor celleducationCells CulturedGlycoproteinsMice KnockoutLiver injuryeducation.field_of_studyMembrane GlycoproteinsMicroscopy ConfocalHepatologyLiver Cirrhosis BiliaryStem CellsLiver cellGastroenterologyFlow Cytometrymedicine.diseaseMolecular biologyMice Inbred C57BLPhenotype030104 developmental biologyGene Expression RegulationLiverChemical and Drug Induced Liver InjuryInflammation MediatorsStromal CellsStem cellSteatohepatitisPeptidesBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation

2020

Background and Aims: Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset of patients are lean, but their underlying pathophysiology is not well understood. Approach and Results: We investigated the role of bile acids (BAs) and the gut microbiome in the pathogenesis of lean NAFLD. BA and fibroblast growth factor (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like phospholipase domain containing 3 (PNPLA3), and transmembrane 6 superfamily member 2 (TM6SF2) variants, and gut microbiota profiles in lean and nonlean NAFLD were investigated in a cohort of Caucasian patients with biopsy-proven NAFLD (n …

Male0301 basic medicineReceptors Cytoplasmic and NuclearGut floraMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseasebiologyMiddle AgedNAFLD; bile acids; fibrosis; gut microbiota; leanPhospholipases A2 Calcium-IndependentFemale030211 gastroenterology & hepatologyfibrosiAdultmedicine.medical_specialtydigestive systemBile Acids and SaltsCyclic N-Oxides03 medical and health sciencesThinnessInternal medicineNAFLDmedicinebile acidAnimalsHumansbile acidsHepatologygut microbiotabusiness.industryFGF15fibrosisnutritional and metabolic diseasesFGF19leanmedicine.diseasebiology.organism_classificationNAFLD fibrosis lean bile acids gut microbiotadigestive system diseasesGastrointestinal MicrobiomeFibroblast Growth FactorsMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyFarnesoid X receptorSteatohepatitisbusinessTropanesTM6SF2
researchProduct

Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis

2018

Non-alcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of histopathological changes ranging from non-inflammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH), which may progress into hepatic fibrosis, cirrhosis, or hepatocellular carcinoma. Recent data suggest that impaired hepatic cholesterol homeostasis and its accumulation are relevant to the pathogenesis of NAFLD/NASH. Despite a vital physiological function of cholesterol, mitochondrial dysfunction is an important consequence of dietary-induced hypercholesterolemia and was, subsequently, linked to many pathophysiological conditions. The aim in the current study was to evaluate the morphological a…

Male0301 basic medicinemedicine.medical_specialtyTime FactorsCirrhosisPhysiologyClinical BiochemistryApoptosisMitochondria LiverMitochondrionDiet High-Fatmedicine.disease_causeMitochondrial DynamicsCholesterol Dietary03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsCells CulturedCell ProliferationCholesterolbusiness.industryFatty liverCell Biologymedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationLiverchemistry030220 oncology & carcinogenesisHepatocyteHepatocytesSteatohepatitisTranscriptomeHepatic fibrosisbusinessOxidative stressJournal of Cellular Physiology
researchProduct

Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: A potential role for bile acids

2017

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, yet the pathogenesis of NAFLD is only partially understood. Here, we investigated the role of the gut bacteria in NAFLD by stimulating the gut bacteria via feeding mice the fermentable dietary fiber, guar gum (GG), and suppressing the gut bacteria via chronic oral administration of antibiotics. GG feeding profoundly altered the gut microbiota composition, in parallel with reduced diet-induced obesity and improved glucose tolerance. Strikingly, despite reducing adipose tissue mass and inflammation, GG enhanced hepatic inflammation and fibrosis, concurrent with markedly elevated plasma and hepatic bile acid l…

Male0301 basic medicineobesityGut floraGalactansGastroenterologyBiochemistryantibioticsMannansSTEATOHEPATITISVoeding Metabolisme en Genomicachemistry.chemical_compoundLiver diseaseEndocrinologyNon-alcoholic Fatty Liver DiseaseFibrosisAntibioticsPlant GumsNonalcoholic fatty liver diseaseHeptaic inflammationFIBROSIShepatic fibrosisResearch ArticlesHuman Nutrition & HealthbiologyBile acidHumane Voeding & GezondheidMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Metabolism and GenomicsAnti-Bacterial Agents3. Good healthIntestineL-CARNITINELiverGUAR GUM[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Metabolisme en Genomica[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Nutrition Metabolism and Genomics[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.medical_specialtymedicine.drug_classBiochemieCelbiologie en ImmunologieQD415-436Gut microbiotaMETABOLISMDiet High-Fatdigestive systemDIET03 medical and health sciencesVoedingINFLAMMATIONINTESTINAL MICROBIOTAInternal medicine[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicineAnimalsHepatic inflammationObesityintestineVLAGNutritionInflammationBile acids and saltshepatic inflammationBiological Transport[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCell BiologyGlucose Tolerance Testmedicine.diseaseTaurocholic acidbiology.organism_classification[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyGastrointestinal MicrobiomeMice Inbred C57BLMICE030104 developmental biologyEndocrinologychemistryCell Biology and ImmunologySteatohepatitisHepatic fibrosisTRIMETHYLAMINE-N-OXIDEHepatic fibrosis
researchProduct

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

2018

Background & Aims: Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic steatosis, but it has not been evaluated in alcoholic liver disease. Therefore, we aimed to validate CAP for the assessment of biopsy-verified alcoholic steatosis and to study the effect of alcohol detoxification on CAP. Methods: This was a cross-sectional biopsy-controlled diagnostic study in four European liver centres. Consecutive alcohol-overusing patients underwent concomitant CAP, regular ultrasound, and liver biopsy. In addition, we measured CAP before and after admission for detoxification in a separate single-centre cohort. Results: A total of 562 patients were included in the s…

MaleAlcoholic liver diseasemedicine.medical_treatmentBiopsyGastroenterologyCohort StudiesSensitivity0302 clinical medicineInterquartile rangeRisk FactorsAlcohol detoxificationNon-invasiveSteatohepatitisUltrasonography2. Zero hungerMetabolic Syndromemedicine.diagnostic_testAlcohol AbstinenceFatty liverAlcohol detoxificationDiagnostic testMiddle Aged3. Good healthAlcoholismLiver030220 oncology & carcinogenesisLiver biopsyControlled attenuation parameterSpecificityElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleFatty Liver AlcoholicAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsFatty liverInternal medicinemedicineHumansFibroScanHepatologybusiness.industryAlcoholic liver diseasemedicine.diseaseCross-Sectional StudiesConcomitantSteatohepatitisSteatosisbusinessJournal of hepatology
researchProduct

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

2021

[Objective] The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD.

MaleDiseaseBody Mass IndexCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseAdult Body Mass Index Cohort Studies Fatty liver Female Humans Male Middle Aged Non-alcoholic Fatty Liver Disease Non-alcoholic steatohepatitis Prognosis Survival Rate Thinness Whitesnonalcoholic steatohepatitis2. Zero hunger0303 health sciencesFatty liverNASHGastroenterologyMiddle AgedPrognosis3. Good healthSurvival RateCohort030211 gastroenterology & hepatologyFemalemedicine.symptomAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAdigestive systemWhite People03 medical and health sciencesThinnessNAFLDInternal medicinemedicineHumansPNPLA3030304 developmental biologyfatty liverbusiness.industryWhitesSettore MED/09 - MEDICINA INTERNAnutritional and metabolic diseasesmedicine.diseaseLean-NASHObesitydigestive system diseasesLean-OutcomesSteatohepatitisbusinessWeight gainBody mass index
researchProduct

Immunopositivity for histone macroH2A1 isoforms marks steatosisassociated hepatocellular carcinoma.

2012

BackgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Prevention and risk reduction are important and the identification of specific biomarkers for early diagnosis of HCC represents an active field of research. Increasing evidence indicates that fat accumulation in the liver, defined as hepatosteatosis, is an independent and strong risk factor for developing an HCC. MacroH2A1, a histone protein generally associated with the repressed regions of chromosomes, is involved in hepatic lipid metabolism and is present in two alternative spliced isoforms, macroH2A1.1 and macroH2A1.2. These isoforms have been shown to predict lung and colon cancer recurrence but to ou…

MalePathologyMouseBiological Markers/metabolismEpidemiologyTumor Microenvironment/geneticsColorectal cancerGene ExpressionHepatocytes/metabolism/pathologyNonalcoholic SteatohepatitisHistonesFatty Liver/chemically induced/complications/genetics/metabolismMice0302 clinical medicineGastrointestinal CancersTumor MicroenvironmentPathologyProtein IsoformsDiethylnitrosamineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateMice KnockoutRegulation of gene expression0303 health sciencesMultidisciplinaryProtein Isoforms/genetics/metabolismbiologyLiver DiseasesPTEN Phosphohydrolase/deficiency/geneticshepatocellular carcinoma biomarker histone variant steatosis epigeneticsLiver NeoplasmsQFatty liverRHistone ModificationAnimal ModelsImmunohistochemistry3. Good healthHistoneOncology030220 oncology & carcinogenesisHepatocellular carcinomaMedicineEpigeneticsCarcinoma Hepatocellular/etiology/genetics/metabolism/pathologyResearch ArticleGene isoformmedicine.medical_specialtyCarcinoma HepatocellularHistologyClinical Research DesignScienceGastroenterology and HepatologyDiet High-Fat03 medical and health sciencesModel OrganismsDiagnostic MedicineGastrointestinal TumorsGeneticsCancer GeneticsCancer Detection and DiagnosisEarly DetectionmedicineAnimalsHumansAnimal Models of DiseaseObesityddc:612BiologyHistones/genetics/metabolismNutrition030304 developmental biologyCell NucleusCell Nucleus/genetics/metabolism/pathologyTumor microenvironmentbusiness.industryPTEN PhosphohydrolaseCancers and NeoplasmsHepatocellular Carcinomamedicine.diseasedigestive system diseasesFatty LiverBiomarker EpidemiologyGene Expression RegulationHepatocytesbiology.proteinLiver Neoplasms/etiology/genetics/metabolism/pathologySteatosisbusinessBiomarkersGeneral Pathology
researchProduct

Hyperferritinemia is a risk factor for steatosis in chronic liver disease.

2009

AIM: To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level. METHODS: One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, HFE gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only. RESULTS: Mean level of ferritin was 881 ± 77 ng/mL in men and 549 ± 82 ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty l…

MalePathologymedicine.medical_specialtyHyperferritinemia chronic liver disease.Chronic liver diseaseGastroenterologyLiver Function TestsRisk FactorsInternal medicinemedicineHumansmedicine.diagnostic_testbiologybusiness.industryLiver DiseasesFatty liverGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseFerritinFatty LiverBrief ArticlesLiver biopsyHereditary hemochromatosisChronic DiseaseFerritinsMutationbiology.proteinAbnormal Liver Function TestFemaleSteatosisSteatohepatitisbusinessWorld journal of gastroenterology
researchProduct

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database

2021

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.MethodsWe analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.ResultsMAFLD was diagnosed in the majority of patients w…

MaleSettore MED/12 - GastroenterologiaCarcinoma HepatocellularLiver Neoplasmsnonalcoholic steatohepatitis.Gastroenterologyhepatocellular carcinomadigestive system diseaseshepatocellular carcinoma; nonalcoholic steatohepatitisNon-alcoholic Fatty Liver DiseaseRisk FactorsHumansnonalcoholic steatohepatitisneoplasms
researchProduct

Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcohol…

2017

BACKGROUND: No study evaluated vascular health markers in subjects with non-alcoholic fatty liver disease (NAFLD) through a combined analysis of reactive hyperemia peripheral arterial tonometry (RH-PAT) and arterial stiffness indexes. AIM OF THE STUDY: We aimed to assess whether NAFLD and its histological severity are associated with impairment of arterial stiffness and RH-PAT indexes in a mixed cohort of patients with biopsy-proven NAFLD. MATERIALS AND METHODS: The Kleiner classification was used to grade NAFLD grade. Pulse wave velocity (PWV) and augmentation index (Aix) were used as markers of arterial stiffness, whereas endothelial function was assessed using reactive hyperemia index (R…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaBiopsyEndocrinology Diabetes and MetabolismHistopathology; Liver fibrosis; Non-alcoholic fatty liver disease030204 cardiovascular system & hematologySeverity of Illness IndexLiver diseaseCognition0302 clinical medicineRisk FactorsPrevalencePulse wave velocityOriginal InvestigationFatty liverMiddle AgedMental Status and Dementia TestsItalyLiverCardiovascular DiseasesCardiologyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyManometryLiver fibrosisHistopathologyHyperemiaPulse Wave Analysis03 medical and health sciencesVascular StiffnessDiabetes mellitusInternal medicineInternal MedicinemedicineHumansReactive hyperemiaAgedbusiness.industryLiver fibrosinutritional and metabolic diseasesmedicine.diseasedigestive system diseasesCross-Sectional StudiesBlood pressurelcsh:RC666-701Case-Control StudiesArterial stiffnessSteatohepatitisCognition Disordersbusiness030217 neurology & neurosurgeryNon-alcoholic fatty liver diseaseCardiovascular Diabetology
researchProduct